The Wall Street Journal looks at efforts to improve how oncologists determine which patients need chemotherapy. What once was a crucial part of cancer treatment might now be best avoided for some patients at low risk. The article cites research from U-M Rogel Cancer Center member Steven Katz, M.D., MPH.
Researchers at the University of Michigan Rogel Cancer Center uncovered a novel gene they named THOR while investigating previously unexplored regions of the human genome -- or the human genome’s dark matter.
After defining the scope of sexual harassment in medicine, a physician says sharing stories and a national reckoning offer hope for progress.
Most cancer immunotherapy research has targeted effector T cells, but a new study steps back and considers: What if the problem isn’t with the effector T cells, but starts higher up the cellular chain? And so researchers looked at naive T cells -- a type of immune cell that hasn’t yet been triggered to fight.
Healthy cells migrate only under special circumstances, such as in the early development of an embryo or when new skin cells and blood vessels move in to repair a wound. For a cancer cell to gain access to the body’s major highways -- the blood vessels and lymphatic system -- it has to invade through something.
University of Michigan Rogel Cancer Center breast cancer researchers discuss the amazing progress of breast cancer research over the past decades and look ahead to the day when it's understood exactly how and why breast cancer spreads so it can be stopped.
Regulatory T cells, or Treg cells, work within the immune system to suppress immune function. Cancer immunotherapy treatments work by supercharging the immune system to fight cancer. So when Tregs come in and suppress the immune response, it shuts down the cancer-fighting effect. But eliminating the Tregs doesn’t help. Researchers have tried, but a clinical trial testing that idea showed no benefit to patients.
Honeycomb-like arrays of tiny, lab-grown cancers could one day help doctors zero in on individualized treatments for ovarian cancer, an unpredictable disease that kills more than 14,000 women each year in the United States alone.
Research has shown that whether or not a patient is married makes a difference in how well -- or not -- a patient does, including for patients with cancer. What researchers don't understand is exactly why being married makes such a difference.
Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.